At BIA’s recent Start-up festival, we caught up with Mark Bartlett, CEO of StoreGene, to learn more about his journey, what drives him, and his advice for founders navigating the world of genomics and startups.
The Mansion House Accord signed on 13 May and the publication of the Government’s Pensions Investment Review mark the latest developments in the BIA’s campaign to unlock pension funds for life sciences. Here, our Director of Policy and External Affairs, Dr Martin Turner, reflects on how we got to this point and what must happen next.
Karen Johal, Senior Director at FTI Consulting LLP, explores how salary sacrifice for pensions offers a smart solution to rising employment costs - helping employers cut costs without cutting staff.
In this blog, Nick Hutchinson, Associate Vice President of Just-Evotec Biologics, provides insight into their new fully continuous end-to-end manufacturing platform while also giving inspiration to young scientists.
We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.
The policy landscape for deep biotech has seen remarkable strides over the past year, positioning the UK as a leader in engineering biology innovation.
The Mansion House Accord fails to sparkle, but as the UK and EU reset relations, our focus turns to opportunities in deep biotech and the need for migration policy to support the talent our sector needs to thrive.
Since joining the TechBio Boost programme, SokerData has refined its business model, adopted a more strategic approach to market entry, built new partnerships and is securing funding to accelerate R&D and commercialisation.
For this Q&A blog, BIA sat down with Annnelise Vuidepot, Chief Technology Officer at Immunocore, to find out about her journey with the company, from its inception to the present day.
In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.
Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).
Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.
